Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.
Saved in:
| Title: | Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. |
|---|---|
| Authors: | Oghalaie A; Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Mahboudi F; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Rahimi-Jamnani F; Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran., Piri-Gavgani S; Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran., Kazemi-Lomedasht F; Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Hassanzadeh Eskafi A; Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Shahbazzadeh D; Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Adeli A; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Talebkhan Y; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Behdani M; Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.; Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran. |
| Source: | Iranian journal of basic medical sciences [Iran J Basic Med Sci] 2022 Mar; Vol. 25 (3), pp. 313-319. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Mashhad University of Medical Sciences Country of Publication: Iran NLM ID: 101517966 Publication Model: Print Cited Medium: Print ISSN: 2008-3866 (Print) Linking ISSN: 20083866 NLM ISO Abbreviation: Iran J Basic Med Sci Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
